SGO Annual Meeting - Sunday/ Monday

Delayed but here are some important tweets from the SGO meeting on Sunday and Monday.


Risk Reducing Salpingectomy and QOL

.@karenluMD presenting important #QOL data regarding risk-reducing salpingectomy in #BRCA mutant #previvors of #OvarianCancer salpingectomy led to decreased cancer worry, low decision regret, and fewer menopausal symptoms #gyncsm #SGOHawaii50 #SGOMtg pic.twitter.com/CFceeOmORX

— Shannon Westin (@ShannonWestin) March 17, 2019

@karenluMD presents important @SU2C #OvarianCancer Dream Team WISP results re delayed oophorectomy vs risk reducing salpingo-oophorectomy in high risk patients. #SGOmtg #gyncsm @ocrahope @NOCC_National pic.twitter.com/76KvvQNwhn

— Annie Ellis (@Stigetta) March 17, 2019

 Phase 1 Levantinib and weekly taxol in recurrent OC

Amazing early results #SGOHawaii50 https://t.co/fHwMds3fNz

— Stephanie Blank (@StephanieVBlank) March 17, 2019

PARP and ARID1A

Representing @VCUMassey at #SGOHawaii50! So much excitement over #PARP - I’m honored to be part of this innovative project! @temkins @emma pic.twitter.com/QUFcuIlkwM

— Stephanie Sullivan (@StephASullivan) March 17, 2019

JAVELIN  - Avelumab+peg liposomal doxorubicin VS peg liposomal doxorubicin

Phase 3 JAVELIN results at #SGOmtg: failed to meet primary endpoint; no overall signif. improvement in PFS or OS w/avelumab+peg liposomal doxorubicin vs. PLD alone in platinum-res/ref epithelial OC, but trend toward improvement in PD-L1+ tumors. #SGOHawaii50 @MDEdgeTweets

— Sharon Worcester (@SW_MedReporter) March 17, 2019

Phase 2 Pembro and Bev

Dr. Zsiros presents P2 results of pembro combo with bev and cyclophosphamide #sgomtg #gyncsm pic.twitter.com/6W5GZ3Gymp

— Annie Ellis (@Stigetta) March 17, 2019

Minorities and clinical trials

This is unacceptable. “Minority patients continue to suffer the greatest consequences.” How can we get more minorities involved in clinical trials?? We need to act on what we know. #SGO50Hawaii #SGOMtg pic.twitter.com/Cs01Yft18H

— Kristin Koerten (@KMKoerten) March 18, 2019

OC Patient Preferences - maintenance therapy

.@LarissaAMeyerMD presents her important work regarding patient preferences for maintenance therapy in #OvarianCancer - patients trust their doctor’s recommendation! #gyncsm #SGOHawaii50 #SGOMtg pic.twitter.com/bleUKGbten

— Shannon Westin (@ShannonWestin) March 18, 2019

CCNE1 and BRD4 Expression and platinum resistance

⁦@riskaMD2014⁩ presenting our work #SGOMTG #SGOHawaii50 #gyncsm. Representing ⁦@KUMedCenter⁩ ⁦@KUcancercenter⁩! pic.twitter.com/uhg9hvx7ii

— DineoKhabeleMD (@DKhabeleMD) March 18, 2019

 Thank you @KMKoerten , @DKhabeleMD, @ShannonWestin, @Stigetta, @SW_MedReporter, @StephASullivan, @StephanieVBlank for posting from the meeting!


Dee
Every Day is a Blessing! 

SGO Meeting Highlights via Twitter ~ Day 4, March 15

Updated with additional tweets 7:32 pm 3/15/17.

Today was the last day of The Society of Gynecologic Oncology (@SGO_org) Annual Meeting (#SGOmtg). Believe it or not as I type this the snow is falling again.

Here are some tweets I found interesting today.

Patient Preferences:
WRITE Symptoms Study (GOG 259):

TY Dr. Donovan for very imp work symptom mgmt & intervention for women living with recurrent #ovariancancer. Understudied! #SGOmtg #gyncsm pic.twitter.com/F0BWU6wts0

— Annie Ellis (@Stigetta) March 15, 2017

@womenofteal top 10 for symptom mgmt: fatigue sleep-disturbance pain anxiety neuropathy constpation memory nausea bloating drowsiness pic.twitter.com/92ySkxfMlZ

— Annie Ellis (@Stigetta) March 15, 2017

@womenofteal pic.twitter.com/3nvk7knJH8

— Annie Ellis (@Stigetta) March 15, 2017

@womenofteal pic.twitter.com/X4QFb3RSpn

— Annie Ellis (@Stigetta) March 15, 2017

Cohn: Understanding patient pref re toxicities critical 2 enhancing shared decision making. YES!!! #SGOMtg Need tools along tx continuum pic.twitter.com/g4kFW1QSLW

— Annie Ellis (@Stigetta) March 15, 2017

Palliative Care:

Nevadunsky: Early palliative care assoc w/improved quality of end of life care #SGOMtg #gyncsm Diverse study population! Very important! pic.twitter.com/8Zss67Ywpr

— Annie Ellis (@Stigetta) March 15, 2017

"Early palliative care is feasible & increases access 4 ethnically/racially diverse women w/ Gyn cancers." Dr. Nevadunsky @SGO2017 #SGOMtg

— Carol Brown (@drcarolbrownMSK) March 15, 2017

Ovarian Cancer:

Myriad data presented at #SGOMtg confirms older mean age at diagnosis of #ovariancancer in BRIP1 and RAD51C germline mutation carriers.

— Douglas Levine MD (@levinemd) March 15, 2017

Chemotherapy Induces Molecular Changes in High-Grade Serous Ovarian Carcinoma #SGOMtg https://t.co/jzLlJXBQtB

— Linus T Chuang (@linuscmd) March 15, 2017

Cervical Cancer

2017 #SGOMtg coverage: High rates of persistent opioid use 6 months after RT for cervical cancerhttps://t.co/DIRlIn5fdl pic.twitter.com/UMWPurj87c

— SGO (@SGO_org) March 15, 2017

A big shout out to all the researchers, gyn oncs, advocates  and others who tweeted from the meeting.Thanks! 

I look forward to April's  #gyncsm chat (April 12, 2017 at 9pm) recapping this year's meeting.

Dee
Every Day is a Blessing!